Connect with others who understand.

sign up log in
Resources
About MyPsoriasisTeam
Powered By
PSORIASIS
NEWS

FDA’s Approval of Cyltezo, a Biosimilar to Humira, May Mean Lower Psoriasis Treatment Costs

Posted on November 17, 2021
Medically reviewed by
Ariel D. Teitel, M.D., M.B.A.
Article written by
Emily Wagner, M.S.
(Grandbrothers - Adobe Stock)

  • The U.S. Food and Drug Administration (FDA) recently approved Cyltezo (adalimumab-adbm), a biosimilar drug that is interchangeable with the already-approved Humira (adalimumab).
  • A phase 3 clinical trial found that there are no differences in safety and efficacy between the two drugs, and Cyltezo is set to be released in the U.S. in July 2023.
  • Biosimilar drugs may be offered at lower prices, reducing health care costs and increasing access to medication.

The FDA has approved Cyltezo, a biosimilar drug that’s interchangeable with Humira, for treating plaque psoriasis, psoriatic arthritis (PsA), and other conditions. Biosimilars such as Cyltezo are designed to function the same as FDA-approved biologic drugs and undergo the same rigorous testing. Doctors and researchers hope biosimilars can lower health care costs and increase access to medication for people living with chronic conditions.

Approved in October and set for release on July 1, 2023, Cyltezo is also used for treating rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and Crohn’s disease. “As the first interchangeable biosimilar of Humira, Cyltezo represents an important step toward bringing patients more affordable treatment options for complex, and often expensive, biologic reference products,” said Dr. Martin Alan Menter, chairman of the division of dermatology at Baylor University Medical Center, in a press release from Cyltezo’s manufacturer Boehringer Ingelheim.

Humira is the world’s top-selling drug. The price of the drug has steadily increased since its approval in 2002. Research from GoodRX from 2020 found that biosimilars cost 10 percent to 37 percent less than biologics, whereas generic medications cost 80 percent to 85 percent less.

How Interchangeable Biosimilar Drugs Are Tested

Cyltezo is the second interchangeable biosimilar treatment to be approved by the FDA. Biosimilar drugs are very close to other biologic drugs that are FDA-approved, but they may be made in a different way or have slightly different structures. Humira is a type of biologic drug referred to as a tumor necrosis factor (TNF) inhibitor.

Although biosimilar drugs are generally less expensive than their name-brand counterparts, they need to be as safe and effective as already-approved drugs. They undergo rigorous testing and clinical trials before being approved in interchangeable studies. These studies look to prove that treatment with either drug will give the same results. Cyltezo was compared to Humira in a randomized phase 3 clinical trial, known as VOLTAIRE-X, and researchers found no differences in safety, efficacy, and effects on the body.

“The biosimilar and interchangeable approval pathway was created to help increase access to treatment options for patients with serious medical conditions,” said Acting FDA Commissioner Dr. Janet Woodcock in a statement from the FDA. “We continue to be steadfast in our commitment to provide patients with alternative high-quality, affordable medications that are proven to be safe and effective.”

Notably, Cyltezo and Humira come with the same potential side effects listed on their respective labels, including the risk of serious infections.

What the Approval of Cyltezo Means

With the FDA’s approval of Cyltezo as an interchangeable alternative, pharmacists will be able to substitute it for Humira without requiring a person’s health care provider to change the prescription. This change works similarly to the pharmacist substituting a generic drug for a brand name one.

Cyltezo may also cost less than Humira, helping improve access to the medication. “We believe that the introduction of biosimilars will improve the lives of patients, as well as contribute to the quality and economic sustainability of health care systems,” said Thomas Seck, senior vice president of medicine and regulatory affairs at Boehringer Ingelheim, in an interview with Healio.

    All updates must be accompanied by text or a picture.
    Ariel D. Teitel, M.D., M.B.A. is the clinical associate professor of medicine at the NYU Langone Medical Center in New York. Review provided by VeriMed Healthcare Network. Learn more about him here.
    Emily Wagner, M.S. holds a Master of Science in biomedical sciences with a focus in pharmacology. She is passionate about immunology, cancer biology, and molecular biology. Learn more about her here.

    Related articles

    Nonsteroidal anti-inflammatory drugs (NSAIDs) are some of the most common treatments used to...

    Meloxicam for Psoriatic Arthritis: 9 Things To Consider

    Nonsteroidal anti-inflammatory drugs (NSAIDs) are some of the most common treatments used to...
    Many people might reach for ointments as a topical treatment for scalp psoriasis. Like other...

    What To Look For in Scalp Psoriasis Ointments

    Many people might reach for ointments as a topical treatment for scalp psoriasis. Like other...
    Emuaid First Aid Ointment is an over-the-counter (OTC) topical therapy that some people find...

    Emuaid for Psoriasis: Is It Effective?

    Emuaid First Aid Ointment is an over-the-counter (OTC) topical therapy that some people find...
    Psoriatic arthritis (PsA) can be managed using a variety of treatment options. These include oral...

    4 Types of Oral Medications for Psoriatic Arthritis

    Psoriatic arthritis (PsA) can be managed using a variety of treatment options. These include oral...
    Treatment for psoriatic arthritis (PsA) can help reduce painful symptoms and control disease...

    8 Treatments for Psoriatic Arthritis: What’s Best for You?

    Treatment for psoriatic arthritis (PsA) can help reduce painful symptoms and control disease...
    Complete skin clearance refers to clearing all evidence of psoriasis from the skin. For people...

    9 Facts About Skin Clearance

    Complete skin clearance refers to clearing all evidence of psoriasis from the skin. For people...

    Recent articles

    MyPsoriasisTeam members sometimes report that their inverse psoriasis has a bad smell. Inverse...

    Does Inverse Psoriasis Have a Smell?

    MyPsoriasisTeam members sometimes report that their inverse psoriasis has a bad smell. Inverse...
    Psoriasis on the buttocks is a type of genital psoriasis. Most people living with this skin...

    How To Identify and Manage Psoriasis on the Buttocks

    Psoriasis on the buttocks is a type of genital psoriasis. Most people living with this skin...
    Psoriatic arthritis (PsA) is an autoimmune disease that can cause symptoms in many parts of your...

    Why Are Your Fingers Twisting Sideways?

    Psoriatic arthritis (PsA) is an autoimmune disease that can cause symptoms in many parts of your...
    Psoriatic arthritis (PsA) is an ongoing condition. If left untreated, it can get worse over time,...

    Can Psoriatic Arthritis Cause Numbness, Tingling, and Neuropathy?

    Psoriatic arthritis (PsA) is an ongoing condition. If left untreated, it can get worse over time,...
    If you have facial psoriasis and facial hair, you may find it difficult to manage your beard....

    6 Tips for Managing Psoriasis Under Your Beard

    If you have facial psoriasis and facial hair, you may find it difficult to manage your beard....
    MyPsoriasisTeam members often wonder how their diet might affect their skin condition and if...

    Carnivore Diet for Psoriasis: Is It Effective?

    MyPsoriasisTeam members often wonder how their diet might affect their skin condition and if...
    psoriasis News
    psoriasis News

    Thank you for subscribing!

    Become a member to get even more:

    sign up for free

    close